Saturday 17 October 2026
Export SLN’s income statement to Excel — free account
Silence Therapeutics PLC Sponsored ADR
Silence Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $559,000.00, down 98.7% from fiscal 2024. In the quarter to June 2026, revenue grew 197.2%, EPS grew 54.4% and free cash flow grew 107.0%, each against the same quarter a year earlier.
8.68
0.67
−7.17%
Follow SLN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | 296.69 | 513.72 | 9.49 | |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
— | (15.95) | (16.61) | (22.51) | |
P/B ratio |
— | 0.00 | 4.61 | 3.31 | |
Price to Tangible BV |
— | 0.00 | 5.59 | 3.88 | |
EV/Sales |
— | 213.24 | 361.63 | 5.54 | |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
— | (2.73) | (3.25) | (1.97) | |
EV/FCF |
— | (2.73) | (3.24) | (1.97) | |
Quick Ratio |
6.40 | 8.82 | 7.87 | 7.16 | |
Current Ratio |
7.42 | 9.83 | 8.72 | 7.69 | |
Net Debt/EBITDA |
5.24 | 4.48 | 6.89 | 3.92 | |
Debt/Assets |
0.00% | 0.04% | 0.05% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.01 | 0.00 | 0.14 | |
Operating CF/Net income |
(0.12) | 1.04 | 1.47 | 0.52 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (0.02) | |
Research and Development Expense of Revenue |
0.00% | 2,161.61% | 25,732.35% | 12,920.75% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 1,664.93% | 10,982.35% | 3,644.65% | |
Intangible Assets out of Total Assets |
0.10 | 0.09 | 0.08 | 0.07 | |
Share Based Compensation of Revenue |
0.00% | 579.86% | (252.94%) | 1,594.34% | |
Graham Net Nets |
— | 0.15 | 0.17 | 0.25 | |
Graham Number |
— | 6.12 | 0.00 | 0.00 | |
Earnings Yield |
— | (30.17%) | (30.76%) | (26.01%) | |
Free Cash Flow Yield |
— | (26.36%) | (21.70%) | (29.61%) | |
Revenue per Share |
0.00 | 0.01 | 0.00 | 0.00 | |
Operating CF per Share |
0.03 | (0.33) | (0.37) | (0.23) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.03 | (0.33) | (0.37) | (0.23) | |
Cash per Share |
1.53 | 1.48 | 1.80 | 2.16 | |
Shareholders Equity per Share |
0.81 | 1.05 | 1.32 | 1.57 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.81 | 1.05 | 1.32 | 1.57 | |
Free Cash Flow |
1.52 | (15.60) | (17.29) | (10.89) | |
Working Capital |
81.57 | 92.39 | 105.05 | 116.25 | |
Capital Expenditures |
— | — | 0.00 | 0.00 | |
Net Current Asset Value |
26.34 | 37.13 | 49.52 | 60.91 | |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.02 | |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
14.67 | 19.53 | 23.69 | 21.86 | |
Average Payables |
13.46 | 14.59 | 14.88 | 17.78 | |
Average Assets |
135.82 | 150.21 | 167.04 | 183.54 | |
Average Common Equity |
66.31 | 31.67 | 98.16 | 98.49 |
Columns are period end dates